Lithera, a San Diego, Calif.-based a clinical stage pharmaceutical company, raised $8m in the final close of its Series C funding.
This brought the total capital raised in this round to $35.6m.
Backers included Alta Partners, Domain Associates, AKS Capital and other unnamed backers.
The company intends to use the funds for general corporate and working capital purposes, primarily to support clinical, regulatory, and manufacturing efforts to advance its lead product candidate, LIPO-202 (Salmeterol Xinafoate for Injection).
Founded in 2007 and led by George Mahaffey, President and CEO, Lithera is advancing LIPO-202 is a novel, physician-administered, injectable pharmaceutical product designed to produce localized non-ablative reduction of subcutaneous abdominal fat. It is currently under development for the reduction of central abdominal bulging in non-obese patients (BMI less than 30 kg/m2).
The company’s LIPO-102 (Salmeterol Xinafoate and Fluticasone Propionate for Injection) is currently under development for the treatment of symptomatic exophthalmos (protrusion of the eye from the orbit) associated with thyroid-related eye disease (also known as Graves’ Orbitopathy).